Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) is now available.
ResMed’s chief financial officer, Brett Sandercock, has reported the sale of 1,000 shares of ResMed common stock at a price of $257.03 per share, leaving him with beneficial ownership of 85,495 shares. The transaction, executed on 2 February 2026, was carried out under a pre-arranged Rule 10b5-1 trading plan adopted in February 2025, signalling that the sale was part of a scheduled diversification or liquidity strategy rather than a discretionary move, and is unlikely to indicate a change in the company’s operational outlook.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$53.20 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. is a global medical technology company specialising in cloud-connected devices and software for the diagnosis, treatment and management of sleep apnea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. The company focuses on improving patient outcomes and reducing healthcare costs through its range of sleep and respiratory care products and digital health solutions, serving both clinical providers and home-care markets worldwide.
Average Trading Volume: 1,047,498
Technical Sentiment Signal: Buy
Current Market Cap: A$54.06B
See more data about RMD stock on TipRanks’ Stock Analysis page.